Description
Transcription
- Elizabeth McMahon
A new breast pathology mock tumor board brings pathologists into the conversation with a patient's care team. Plus, identifying multiple diseases with a single blood sample. How AI is changing the game. This is the Path News Network Daily Edition from the College of American Pathologists. I'm Elizabeth McMahon. It's Thursday, April 9th. The public health community is hoping to get a better picture of how measles is spreading in the U.S. following the release of 1,000 measles genomes by the Centers for Disease Control. The CDC has been hit hard by layoffs and resignations, delaying the release of the data on viral genomes. The data will help health officials determine whether the U.S. has lost its measles elimination status, which it's held since 2000 and reflects the nation's vaccination rates. Dr. Ben Bradley, vice chair of the CAP's Microbiology Committee, says the data provides crucial clues about whether cases are linked and how they're moving, though gaps remain.
- Dr. Ben Bradley
These outbreaks at least have started in communities that are maybe more skeptical of going to medical providers, are more skeptical of receiving treatment, and so if these people do get sick... They're probably not going to go to get tested for measles. They're just going to say, I guess I had measles and that's that. So, you know, the numbers that we're seeing of positive cases are, I think, a very large underestimate of the total burden of disease that's been there.
- Elizabeth McMahon
Dr. Bradley, an assistant professor of pathology at the University of Utah, says that understanding the scope of the outbreak and its transmission helps labs plan surveillance and strategy.
- Dr. Ben Bradley
A lot of laboratories and state public health labs you built out wastewater testing during COVID. And at least in Utah, we've been able to leverage some of that wastewater testing to now do it for measles. And so if we have a better sense of kind of the transmission situation nationally, some of these states might be incentivized or feel more strongly about kind of doing more surveillance in their communities for measles to potentially find cases that maybe they weren't aware of.
- Elizabeth McMahon
The CDC data release comes as new measles cases were identified in California and Oregon this week. A breast cancer diagnosis may start with a pathology report, but interpreting the results and determining treatment goes to expert partners far beyond the laboratory. On May 20, pathologists will explore six breast cancer cases with experts in breast pathology, surgery, medical and radiation oncology, and radiology. It's all part of the CAP's new multidisciplinary breast pathology mock tumor board. The session's multidisciplinary approach gives pathologists at all career stages the opportunity to hear perspectives that can be helpful, especially in cases where there's uncertainty, says Dr. Bradley Turner, a tumor board faculty member and professor of pathology and laboratory medicine at the University of Rochester Medical Center. He uses ductal carcinoma in situ, or DCIS, versus atypical ductal hyperplasia, or ADH, as examples.
- Dr. Bradley Turner
There are borderline cases where we may not be quite sure whether we want to call it DCIS or ADH. And it may be important to the clinician to know about this uncertainty, because if we call it DCIS, it potentially may mean radiation or more surgery. If we call it ADH, it may mean nothing. No further treatment. So even though we may be unsure because of, you know, borderline cases, it may be important for the clinician to know that. And it may be important for the pathologist to understand the clinician's perspective before we make the diagnosis.
- Elizabeth McMahon
Tumor Board co-faculty member Dr. Huina Zhang, also of the University of Rochester Medical Center, says the Tumor Board will also touch on advances in breast cancer testing and practical implications for patients. Register for the virtual mock Tumor Board and learn more about the available CME credits at the link on the CAP homepage. Researchers have developed an AI model that shows it's possible to detect several neurodegenerative diseases from a single blood sample. A research team at Sweden's Lund University created the AI model based on protein measurements from more than 17,000 patients and control participants in the Global Neurodegenerative Proteomics Consortium database. The consortium houses more than 40,000 patient samples from international research groups. The team used advanced statistical learning methods to train the model, which correctly identified a specific set of proteins that form patterns for diseases involving brain degeneration. They also found the protein profile predicted cognitive decline better than clinical diagnoses. The team published their findings March 31st in the journal Nature Medicine. And finally, it's the place to be this fall. CAP26, running October 3rd through 6th, is taking shape with exciting events and sessions all within the luxurious oasis of the Wynn Las Vegas. What's on tap? Amid the exhibits, workshops, networking, and fun, don't miss the plenary session on using and implementing digital pathology in the era of AI. You'll hear from experts in pathology informatics, lab administration, and other areas. that can help you sustain a thriving digital pathology practice. Come away with insights and practical strategies on the components you need for integrating AI and advanced digital workflows into your clinical practice. Find out more and register to attend at the CAP26 tab under Events on the CAP homepage. That's all for today's Daily Edition. Be sure to check the show notes for more information on today's stories. Watch your inbox for more news like this. in the CAP's advocacy newsletter every Tuesday and our weekly edition newsletter on Thursdays. We're back at 5 a.m. Eastern for another episode of The Daily Edition. I'm Elizabeth McMahon. Have a great day.
Description
Transcription
- Elizabeth McMahon
A new breast pathology mock tumor board brings pathologists into the conversation with a patient's care team. Plus, identifying multiple diseases with a single blood sample. How AI is changing the game. This is the Path News Network Daily Edition from the College of American Pathologists. I'm Elizabeth McMahon. It's Thursday, April 9th. The public health community is hoping to get a better picture of how measles is spreading in the U.S. following the release of 1,000 measles genomes by the Centers for Disease Control. The CDC has been hit hard by layoffs and resignations, delaying the release of the data on viral genomes. The data will help health officials determine whether the U.S. has lost its measles elimination status, which it's held since 2000 and reflects the nation's vaccination rates. Dr. Ben Bradley, vice chair of the CAP's Microbiology Committee, says the data provides crucial clues about whether cases are linked and how they're moving, though gaps remain.
- Dr. Ben Bradley
These outbreaks at least have started in communities that are maybe more skeptical of going to medical providers, are more skeptical of receiving treatment, and so if these people do get sick... They're probably not going to go to get tested for measles. They're just going to say, I guess I had measles and that's that. So, you know, the numbers that we're seeing of positive cases are, I think, a very large underestimate of the total burden of disease that's been there.
- Elizabeth McMahon
Dr. Bradley, an assistant professor of pathology at the University of Utah, says that understanding the scope of the outbreak and its transmission helps labs plan surveillance and strategy.
- Dr. Ben Bradley
A lot of laboratories and state public health labs you built out wastewater testing during COVID. And at least in Utah, we've been able to leverage some of that wastewater testing to now do it for measles. And so if we have a better sense of kind of the transmission situation nationally, some of these states might be incentivized or feel more strongly about kind of doing more surveillance in their communities for measles to potentially find cases that maybe they weren't aware of.
- Elizabeth McMahon
The CDC data release comes as new measles cases were identified in California and Oregon this week. A breast cancer diagnosis may start with a pathology report, but interpreting the results and determining treatment goes to expert partners far beyond the laboratory. On May 20, pathologists will explore six breast cancer cases with experts in breast pathology, surgery, medical and radiation oncology, and radiology. It's all part of the CAP's new multidisciplinary breast pathology mock tumor board. The session's multidisciplinary approach gives pathologists at all career stages the opportunity to hear perspectives that can be helpful, especially in cases where there's uncertainty, says Dr. Bradley Turner, a tumor board faculty member and professor of pathology and laboratory medicine at the University of Rochester Medical Center. He uses ductal carcinoma in situ, or DCIS, versus atypical ductal hyperplasia, or ADH, as examples.
- Dr. Bradley Turner
There are borderline cases where we may not be quite sure whether we want to call it DCIS or ADH. And it may be important to the clinician to know about this uncertainty, because if we call it DCIS, it potentially may mean radiation or more surgery. If we call it ADH, it may mean nothing. No further treatment. So even though we may be unsure because of, you know, borderline cases, it may be important for the clinician to know that. And it may be important for the pathologist to understand the clinician's perspective before we make the diagnosis.
- Elizabeth McMahon
Tumor Board co-faculty member Dr. Huina Zhang, also of the University of Rochester Medical Center, says the Tumor Board will also touch on advances in breast cancer testing and practical implications for patients. Register for the virtual mock Tumor Board and learn more about the available CME credits at the link on the CAP homepage. Researchers have developed an AI model that shows it's possible to detect several neurodegenerative diseases from a single blood sample. A research team at Sweden's Lund University created the AI model based on protein measurements from more than 17,000 patients and control participants in the Global Neurodegenerative Proteomics Consortium database. The consortium houses more than 40,000 patient samples from international research groups. The team used advanced statistical learning methods to train the model, which correctly identified a specific set of proteins that form patterns for diseases involving brain degeneration. They also found the protein profile predicted cognitive decline better than clinical diagnoses. The team published their findings March 31st in the journal Nature Medicine. And finally, it's the place to be this fall. CAP26, running October 3rd through 6th, is taking shape with exciting events and sessions all within the luxurious oasis of the Wynn Las Vegas. What's on tap? Amid the exhibits, workshops, networking, and fun, don't miss the plenary session on using and implementing digital pathology in the era of AI. You'll hear from experts in pathology informatics, lab administration, and other areas. that can help you sustain a thriving digital pathology practice. Come away with insights and practical strategies on the components you need for integrating AI and advanced digital workflows into your clinical practice. Find out more and register to attend at the CAP26 tab under Events on the CAP homepage. That's all for today's Daily Edition. Be sure to check the show notes for more information on today's stories. Watch your inbox for more news like this. in the CAP's advocacy newsletter every Tuesday and our weekly edition newsletter on Thursdays. We're back at 5 a.m. Eastern for another episode of The Daily Edition. I'm Elizabeth McMahon. Have a great day.
Share
Embed
You may also like